These success, together with a preceding report demonstrating that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like conduct in mice,2 support the idea of concentrating on ACKR3 as a novel approach to modulate the opioid process, which could open new therapeutic avenues for opioid-